XPC and prostate carcinoma: The Gleason grade categorises patients with prostate cancer based on cell differentiation; the XPC PAT I/I genotype displayed a 2.8-fold increased risk of a high Gleason grade (Adjusted OR-2.88, 95% CI 1.22–6.79, p = 0.015).